吉非替尼联合洛铂胸腔内灌注治疗肺癌恶性胸水的临床观察  

Clinical study of gefitinib targeted therapy combined with intrapleural infusion of lobaplatin in the treatment of malignant pleural effusion of lung cancer

作　　者：刘日清 黄仁林 梁柱 LIU Ri-qing;HUANG Ren-lin;LIANG Zhu(Department of Cardiothoracic Surgery, Lianjiang People’s Hospital, Lianjiang 524400, China;Department of Cardiothoracic Surgery, the Affiliated Hospital of Guangdong Medical University, Zhanjiang 524021, China)

机构地区：[1]广东省廉江市人民医院心胸外科,广东廉江524400 [2]广东医科大学附属医院心胸外科,广东湛江245021

出　　处：《广东医科大学学报》2019年第4期443-445,共3页Journal of Guangdong Medical University

基　　金：湛江市科技计划项目(No.180608161684337)

摘　　要：目的观察吉非替尼联合洛铂胸腔内灌注治疗肺癌恶性胸水的临床疗效。方法选取2015年2月至2016年2月收治的60例肺癌合并恶性胸水的患者作为研究对象,随机分为对照组和实验组,每组30例。两组患者均给予胸腔闭式引流排除胸水,对照组给予洛铂胸腔内灌注治疗,实验组在对照组治疗的基础上联用吉非替尼靶向治疗。比较两组患者的临床疗效、生活质量改善情况、不良反应,以及患者的远期生存率。结果实验组患者的治疗效果、生活质量改善程度以及治疗后3 a内的生存情况均明显优于对照组(P<0.05或0.01),且两组患者治疗期间不良反应的发生情况比较差异无统计学意义(P>0.05)。结论吉非替尼联合洛铂胸腔内灌注治疗能够改善肺癌恶性胸水的临床疗效。Objective To study the clinical effect of gefitinib targeted therapy combined with intrapleural infusion of lobaplatin in the treatment of malignant pleural effusion of lung cancer. Methods A total of 60 cases with lung cancer complicated with malignant pleural effusion admitted to our department from February 2015 to February 2016 were enrolled in the study. The patients were randomly divided into the Experimental Group and the Control Group, 30 cases in each group. Both groups were treated with thoracic close drainage to remove pleural effusion. The patients in the Control Group were treated with intrapleural infusion of lobaplatin while the patients in the Experimental Group were treated with gefitinib targeted therapy based on the treatment for the Control Group. The clinical efficacy, improvement in the quality of life, adverse reactions and long-term survival rate of the two groups were compared and evaluated. Results The therapeutic effect, the improvement in the quality of life and the survival within 3a of the Experimental Group was significantly superior to those of the Control Group (P<0.05 or 0.01). There was no significant difference in adverse reactions between the two groups during the treatment (P>0.05). Conclusion Gefitinib targeted therapy combined with intrapleural infusion of lobaplatin can improve the clinical efficacy of malignant pleural effusion of lung cancer.

关 键 词：吉非替尼 洛铂 恶性胸水 

分 类 号：R734[医药卫生—肿瘤]